Prothena Corp Reaches New 12-Month High at $32.25 (PRTA)
Prothena Corp (NASDAQ:PRTA)’s share price reached a new 52-week high during mid-day trading on Thursday, Analyst Ratings Network reports. The stock traded as high as $32.25 and last traded at $32.25, with a volume of 416,950 shares traded. The stock had previously closed at $29.79.
Several analysts have recently commented on the stock. Analysts at Credit Suisse reiterated an “outperform” rating on shares of Prothena Corp in a research note to investors on Thursday, December 12th. They now have a $35.00 price target on the stock, up previously from $32.00. Separately, analysts at Merrill Lynch initiated coverage on shares of Prothena Corp in a research note to investors on Friday, November 15th. They set a “neutral” rating on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of Prothena Corp in a research note to investors on Friday, November 15th. They set a “neutral” rating and a $28.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Prothena Corp has an average rating of “Buy” and an average target price of $30.25.
Prothena Corp has a 1-year low of $5.90 and a 1-year high of $30.55. The stock’s 50-day moving average is $27.20 and its 200-day moving average is $22.68. The company’s market cap is $700.0 million.
Prothena Corporation plc is a biotechnology company. The Company focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.